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Abstract
Sarcoidosis is a rare, multi-systemic, inflammatory disease, primarily
affecting the lungs. High-resolution computed tomography (CT) scans are
used to clinically characterize pulmonary sarcoidosis. In the medical imag-
ing field, there is growing recognition to switch from visual examination of
CT images to more rapid, objective assessments of the abnormalities. In
this work, we explore the usefulness of various objective measures of spa-
tial heterogeneity—fractal dimension, Moran’s I, and Geary’s C —for dis-
tinguishing between abnormal sarcoidosis and normal lung parenchyma.
CT data for N=58 sarcoidosis subjects enrolled at National Jewish
Health were obtained from the GRADS study. CT data for N=101 control
patients were obtained from the COPDGene study. Radiomic measures
were computed for each two-dimensional slice of a given scan, in the axial,
coronal, and sagittal planes. Functional regression was applied to identify
lung regions where CT nodules tend to proliferate.
Moran’s I, Geary’s C and fractal dimension significantly differentiate
between subjects with and without sarcoidosis throughout the majority of
the lung, with disease abnormalities most apparent in the top axial, mid-
dle coronal, and outer sagittal regions. A trend appeared across Scadding
stages, with CT scans from patients with Scadding stages I and III ap-
pearing the healthiest, and Scadding stage IV appearing the least healthy.
The radiomic measures and techniques presented herein successfully
characterize CT images in sarcoidosis by objectively and efficiently ap-
proximating what we know about the pathology of sarcoidosis.
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1 Introduction
Sarcoidosis is a rare, multi-systemic, inflammatory disease, primarily affecting
the lungs, lymph nodes, eyes and skin. Although the etiology of sarcoidosis is
unknown, the combination of environmental and genetic factors are important
in understanding disease risk. Sarcoidosis affects 4.7 to 64 per 100,000 per-
sons, with seasonal peaks in the spring, and the highest rates found in northern
European and African-American females (Valeyre et al. 2014). While sponta-
neous remission may occur in up to two thirds of subjects in certain populations
(Nunes et al. 2005), mortality rates due to respiratory failure are rising in the
US (Swigris et al. 2011).
Pulmonary sarcoidosis is a common presentation of sarcoidosis, as lung in-
volvement affects 95% of those with the disease. Symptoms include cough,
chest discomfort, and poor pulmonary function as measured by FVC, FEV1,
and total lung capacity (Butler and Keane 2016). Clinical and radiological
presentations are used for diagnosis of pulmonary sarcoidosis, with chest ra-
diographs showing abnormalities in 90% of cases (Valeyre et al. 2014). The
Scadding system of staging classifies subjects with sarcoidosis into five stages:
stage 0 (no radiograph abnormalities), stage 1 (bilateral hilar lymphadenopathy
(BHL) alone), stage 2 (pulmonary infiltration with BHL), stage 3 (pulmonary
infiltration without BHL), and stage 4 (pulmonary fibrosis with volume loss).
Pulmonary infiltration is characterized by small nodular opacities that track
along the bronchovascular bundle; these opacities are usually bilateral, sym-
metrical, and predominately in the central regions and upper lobes. BHL is an
enlargement of the lymph nodes that are in or surrounding the mediastinum. A
wide range of additional chest radiographic patterns may be observed, includ-
ing: focal alveolar and ground-glass opacities, pleural thickening or calcification,
upper lobe volume loss with hilar retraction, coarse linear bands, and bullae. In
general, as the disease worsens, these patterns become more prominent (Nunes
et al. 2005). However, despite the nomenclature, there is no sequential ordering
of Scadding stages, and subjects may or may not experience any of the stages
at various times during their diagnosis.
High-resolution computed tomography (CT) scans are used to clinically char-
acterize sarcoidosis. Some studies have shown the ability of CT scans to dif-
ferentiate between patients with interstitial lung disease and healthy controls
(Sluimer et al. 2006). However, these studies rely on visual examination of
CT scans by pulmonologists and radiologists. Visual examination of disease on
medical images is time consuming and known to have poor inter-rater reliability
(Wormanns et al. 2000). Thus, in the field of medical imaging, there is a grow-
ing recognition that switching to automated reads of CT scans would provide a
number of advantages, including a more rapid and objective assessment of the
abnormalities.
Unlike sarcoidosis, objective assessments are increasingly finding application
for quantification of disease severity on CT scans of subjects with emphysema.
Measures and approaches include percentage of low attenuation, mean lung den-
sity, histogram analysis, and Adaptive Multiple Feature Method (Uppaluri et
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al. 1997). However, there is a lack of objective methods to quantify disease
severity of sarcoidosis, due to disease relative rarity and unique manifestations
on CT scans. That is, sarcoidosis presents on CT scans as areas of high at-
tenuation (opposite of emphysema), which, problematically, is similar to the
presentation of airways and vasculature of the lung. Often, unwanted tissues
can be masked from CT scans in pre-processing; yet, masking of airways and
vasculature in subjects with sarcoidosis can be difficult (Nardelli et al. 2015). As
such, the presentation of sarcoidosis in the lungs is muddled with ‘background
noise’, which limits the applicability of standard objective CT quantification
biomarkers, such as percentage of attenuation, to quantify disease severity of
sarcoidosis.
Due to the presence of visual patterns in pulmonary CT images of subjects
with sarcoidosis, we turn to spatial measures to objectively quantify and describe
these data. In this work, we will investigate various putative spatial radiomic
biomarkers, including Moran’s I, Geary’s C, fractal dimension and Mate´rn pa-
rameters, to differentiate between subjects with and without sarcoidosis. To
identify regions of the lung where disease tends to proliferate, a slice-by-slice
functional analysis will be performed in the three anatomical planes (axial,
coronal, and sagittal). The axial (or transverse) plane divides the body into
top and bottom portions (i.e. cranial and caudal); the coronal plane divides
the body into back and front (i.e. posterior and anterior); the sagittal plane
divides the body into right and left portions. The novelty of our approach lies
in comprehensively examining spatial radiomic features in sarcoidosis tissue of
the lung, and identifying lung regions of interest in a time- and space-efficient
computation.
2 Spatial Radiomic Measures
2.1 Moran’s I
Spatial autocorrelation is a measure of similarity between values located in
space. One popular attempt at summarizing spatial autocorrelation is Moran’s
I. Moran’s I relies on the product moments of values located in space. However,
only the product moments between pixels at a specific distance are considered
in the calculation. The collection of distances included is known as the “neigh-
borhood”.
Moran’s I is, arguably, the most common measure of spatial autocorrelation,
and is often used in exploratory data analysis for areal data (Banerjee et al.
2014). While there are proposed modifications and alternatives to Moran’s I
(Maruyama 2015), we rely on the original estimate as proposed by Moran (1950).
Moran’s I is given by:
I = n∑n
i=1
∑n
j=1 wij
∑n
i=1
∑n
j=1 wij(yi − y¯)(yj − y¯)∑n
i=1 (yi − y¯)2
(1)
where n is the number of non-missing pixels; wij is an element in the spatial
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weight matrix (W ); yi is the HU intensity at a single pixel; y¯ is the mean HU
intensity over the whole slice, y˜ = yi − y¯; and I is the identity matrix.
Various spatial weight matrices can be used in this estimation. The original
and most common weight matrices for Moran’s I are the four or eight nearest
neighbor matrices. The range of Moran’s I depends on its spatial weight matrix.
As shown by Maruyama (2015), Moran’s I is bound between the smallest and
second-largest eigenvalues of its spatial weight matrix. Regardless of the weight
matrix used, values around zero are indicative of no spatial autocorrelation, with
higher values indicating a positive spatial autocorrelation. Since CT nodules
begin to conglomerate in sarcoidosis subjects, we hypothesize that sarcoidosis
subjects will have higher values for Moran’s I as compared to healthy controls.
2.2 Geary’s C
Geary’s C (Geary 1954) is also a measure of spatial autocorrelation. It differs
from Moran’s I in that it is more sensitive to smaller scale spatial structures,
due to its reliance on squared differences, rather than on product moments.
Geary’s C is given by:
C =
(n− 1)
2
∑n
i=1
∑n
j=1
∑n
i=1
∑n
j=1 wij(yi − yj)2∑n
i=1 (yi − y¯)2
(2)
where L = D −W ; D is the diagonal matrix; n is the number of non-missing
pixels; wij is an element in the spatial weight matrix (W ); yi is the HU intensity
at a single pixel; y¯ is the mean HU intensity over the whole slice; and z˜ = yi−yj .
Similar to Moran’s I, various spatial weight matrices can be used.
Geary’s C ranges from 0 to 2, with values close to zero indicating strong
positive spatial autocorrelation, values close to two indicating strong negative
spatial autocorrelation, and a value of one indicating no spatial autocorrelation.
Since Geary’s C is inversely proportional to Moran’s I, we hypothesize that
sarcoidosis subjects will have lower values of Geary’s C as compared to healthy
controls.
2.3 Fractal dimension
Fractal dimension differs from Moran’s I and Geary’s C, in that it is inherently
a measure of point-level spatial data. Commonly referred to as a property of
statistical self-similarity or complexity, fractal dimension is also a measure of
roughness, as the spatial scale becomes infinitesimally small (Gneiting et al.
2010).
There are various methods to estimate fractal dimension on two-dimensional
spatial domains. However, Gneiting et al. (2010) showed that the line transect
madogram estimator, based on the power (Vˆ ) and variation estimates (Dˆ) is
both efficient and robust. Fractal dimension estimated with the line transect
madogram is defined as:
D = 1 + median{Dˆk} (3)
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where k represents the index for the row or column line transect, and Dˆk is the
fractal dimension estimate for a single line transect, defined as:
Dˆk = 2− log Vˆk(2)− log Vˆk(1)
log 2
(4)
Vˆk(l) =
1
2(mk − l)
∑
∀i,j∈|i−j|=l
|zi − zj | (5)
where Vˆk(l) represents the variation in a single line transect at the amount of
lag, l (or difference in distance between two pixels, i and j), and mk is the
number of differences in a single line transect k such that |i− j| = l.
In two-dimensional space, such as a slice of a CT scan, fractal dimension
ranges between 2 and 3. Low fractal values are indicative of the lack of self-
similarity patterns, and may be characterized as ‘smooth’; whereas high values
indicate self-similarity patterns, and may be characterized as ‘rough’. Since sar-
coidotic tissue disrupts the inherent self-similarity pattern seen in the healthy
lung, we hypothesize that fractal dimension will be lower in subjects with sar-
coidosis as compared to healthy controls.
3 Methods
3.1 Data acquisition
The CT data for sarcoidosis subjects enrolled at National Jewish Health were
obtained from the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sar-
coidosis (GRADS) study. The GRADS study is a multi-center, observational
cohort study exploring the role of the microbiome and genome in subjects with
Alpha-1 Antitrypsin Deficiency and/or Sarcoidosis (Moller et al. 2015). Ap-
proximately 358 sarcoidosis subjects were enrolled across the entire program
after undergoing informed consent for a protocol that was approved by the sites
IRB; however, the present study focuses on subjects with sarcoidosis seen at
National Jewish Health (NJH) in Denver, Colorado. At NJH, 79 subjects with
varying stages of sarcoidosis were enrolled in the study, including N=58 sub-
jects with Scadding stage I-IV chest radiographs. As part of the GRADS study,
uniform clinical data was obtained including self-administered questionnaires,
pulmonary function testing, a chest radiograph (for Scadding staging classifi-
cation), and a research chest CT. All research chest CTs were acquired using
Siemens SOMATOM Definition, with the participants in the supine position
during breath holding at end inspiration, and the following machine parame-
ters: 500msec exposure time, B35f kernel, and 0.75mm thickness (Moller et al.
2015).
CT data for control subjects were obtained from the COPDGene study.
COPDGene is a cross-sectional prospective cohort exploring epidemiological
and genetic characteristics in smokers with and without COPD (Regan et al.
2010). Since smoking is protective for sarcoidosis, few subjects had a history
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of smoking; hence, we included only only healthy, non-smoking subjects in the
present study. These subjects received chest CT scans using the same protocol
as the GRADS study. All CT scans and data in this study were provided with
a de-identified study ID number without any identifying information.
3.2 Data-processing
CT scans for subjects with sarcoidosis were received in NIfTI-1 file format.
Healthy controls were received in DICOM format, then converted to NIfTI-1
file format using function, ‘dicom2nifti’, available in the ‘oro.dicom’ v0.5.0 R
package. All scans were unscaled. Masks were applied to segment the right and
left lungs, and checked for quality using visual inspection and slice standard
deviations. All Hounsfield units (HU) outside the standard CT window setting
for pulmonary parenchyma (center: -500 HU, width: 1800 HU) (Teague et al.
2012) were removed due to inaccurate masking. Slices with less than 10,000
pixels (approximately 5% or less of total slice) were discarded due to small
image size and inaccurate estimates. To reduce computation time, every third
slice for every CT scan was summarized by fractal dimension, Moran’s I, and
Geary’s C in the three anatomical planes: axial, coronal, and sagittal.
Moran’s I and Geary’s C were calculated using the eight nearest neigh-
bor adjacency matrix. Fractal dimension was estimated using the line transect
madogram estimator. All three– Moran’s I, Geary’s C, and fractal dimension–
were custom-coded in RStudio v1.0.136.
3.3 Statistical analysis
Descriptive statistics (e.g. mean and standard deviation for continuous vari-
ables; frequency tables for categorical variables) were used to summarize de-
mographic and pulmonary function data. To test for an association between
disease group and gender, a Chi-square test was used. To test for an association
between disease group and race (white/non-white), a Fisher’s exact test was
used, due to small cell sample sizes. Independent two-sample t-tests assuming
unequal variance were used to test for a difference in means for all continuous
variables between disease groups.
To determine whether the putative radiomic biomarkers differed throughout
the slices of the lungs between subjects with and without sarcoidosis, functional
regression was used. Given the imbalance in covariates, the functional regres-
sion was extended to adjust for gender, age, and BMI. This analysis was inde-
pendently performed for fractal dimension, Moran’s I, Geary’s C, and Mate`rn
parameters. Mean estimates and standard errors for each parameter were plot-
ted to understand the patterns of the putative spatial biomarkers throughout
the lung. All analyses were performed in Rstudio v1.0.136.
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4 Results
4.1 Demographics and clinical characteristics
In this study, 159 people with CT scans were analyzed, of which 58 had sarcoido-
sis. In the sarcoidosis group, the majority were white (87.9%), male (55.2%),
with a mean age of 54.1 years (SD: 9.0 years) and a BMI of 28.8 (SD: 6.2). In the
control group, the majority were white (94.1%), female (68.3%), with a mean
age of 62.1 years (SD: 9.1 years) and a BMI of 28.0 (SD: 4.9). The sarcoido-
sis group had a significantly higher percentage of males (p=0.006), lower mean
age (p<0.001), and higher height (p=0.001) and weight (p=0.019) (Table 1).
Additionally, the sarcoidosis group had a significantly lower percent predicted
post-bronchodilator FEV1 (p<0.001) and FVC (p<0.001)) (Table 2).
4.2 Behavior of radiomic features for selected representa-
tive subjects
To illustrate the patterns in the radiomic biomarker information obtained across
the range of disease, we examine the values from three representative individ-
uals, from healthy, mildly abnormal (Sarc A), and very abnormal (Sarc B) CT
scans. As disease becomes more apparent on the CT slices (from healthy to
very abnormal) (Figure 1), the values for Moran’s I increase. In contrast, the
values for fractal dimension and Geary’s C decrease (Tables 3, 4, 5). An increase
in Moran’s I and a decrease in Geary’s C are indicative of more positive spa-
tial autocorrelation; a decrease in fractal dimension D is indicative of smoother
structures. The trend in these parameters are clinically important, since we
expect to see more positive spatial autocorrelation and smoother structures in
CT slices as disease worsens.
4.3 Moran’s I
For all subjects, Moran’s I ranges from 0.45 to 0.97 units, indicative of positive
spatial structure. In the axial plane, Moran’s I is highest in the middle of
the lung, and lowest at the bottom and top of the lung. In the coronal plane,
Moran’s I is highest in the middle of the lung, and lowest at the back and
front of the lung. In the sagittal plane, Moran’s I is mid-range on the outside
right and left of the lungs, then drops to its lowest at the center of the lungs
(Figure 2). These results indicate that the lung shows the most global spatial
structure in the middle axial, coronal, and sagittal regions, and the least spatial
structure in the bottom/top axial, back/front coronal, and inner sagittal.
Without adjusting for covariates (Figure 2), Moran’s I significantly differ-
entiates between subjects with and without sarcoidosis in certain regions of the
lung. The areas with the most differentiation between diseased and control sub-
jects are the top axial, middle coronal, and outer sagittal regions. In general,
subjects with sarcoidosis have higher Moran’s I than healthy controls, indica-
tive of more positive spatial structures. These results are similar in both the
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right and left lungs.
Moran’s I shows a trend across healthy controls and stages of sarcoidosis
(Figure 3). In general, healthy subjects have the lowest Moran’s I, and sar-
coidosis subjects classified as stage IV have the highest Moran’s I, as we would
expect. The trend in the stages from lowest to highest Moran’s I is as follows:
Stage I and Stage III, Stage II, and Stage IV. This trend is most apparent in
the top axial, middle coronal, and outer left/right sagittal regions.
4.4 Geary’s C
For all subjects, Geary’s C ranges from 0.03 to 0.42 units, indicative of positive
spatial structure. In the axial plane, Geary’s C is lowest in the middle of the
lung, and highest at the bottom and top of the lung. In the coronal plane,
Geary’s C is lowest in the middle of the lung, and highest at the back and front
of the lung. In the sagittal plane, Geary’s C is lowest on the middle of the right
and left of the lungs, and highest at the inner part (towards the center of the
body) (Figure 4). These results indicate that the lung shows the most local
spatial structure in the middle axial, coronal, and sagittal regions, and the least
spatial structure in the bottom/top axial, back/front coronal, and inner sagittal
regions.
Without adjusting for covariates (Figure 4), Geary’s C significantly differen-
tiates between subjects with and without sarcoidosis. The areas with the most
differentiation between diseased and control subjects are the top axial, middle
coronal, and outer sagittal regions. In general, subjects with sarcoidosis have
lower Geary’s C than healthy controls, indicative of more local, positive spatial
structures.
Geary’s C also shows a trend across healthy controls and stages of sarcoido-
sis (Figure 5). In general, healthy subjects have the highest Geary’s C, and
sarcoidosis subjects classified as stage IV have the lowest, as we would expect.
Similar to Moran’s I, the trend in the stages from highest to lowest Geary’s C
is as follows: Stage I and Stage III, Stage II, and Stage IV. This trend is most
apparent in the top axial, middle coronal, and outer left/right sagittal regions.
4.5 Fractal Dimension, D
For all subjects, fractal dimension ranges from 2.12 to 2.61 units. In the axial
plane, fractal dimension is highest at the bottom of the lung, and lowest in the
middle of the lung. In the coronal plane, fractal dimension is fairly constant from
the back slices to the front. In the sagittal plane, fractal dimension is highest in
the middle of the lungs, and lowest on the outer right and left slices (Figure 6).
These results indicate that the lung is “roughest” and most“self-similar” at the
bottom axial and inner sagittal, and “smoothest” and least “self-similar” at the
middle axial and outer sagittal regions.
Fractal dimension significantly differentiates between subjects with and with-
out sarcoidosis (Figure 6). Subjects with sarcoidosis have significantly lower
8
fractal dimension than healthy controls in nearly all parts of the lung, regard-
less of right/left lung and anatomical orientation. This is indicative of a lower
degree of self-similarity and more smoothness in sarcoidosis subjects as com-
pared to controls throughout the entire lung.
There is also a trend in fractal dimension across healthy controls and stages
of sarcoidosis (Figure 7). In general, healthy subjects have the highest fractal
dimension, and sarcoidosis subjects classified as stage IV have the lowest fractal
dimension, as we would expect. The trend across stages from highest to lowest
FD does not following the staging progression and is as follows: Stage III, Stage
I, Stage II, and Stage IV.
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Table 1: Subject Characteristics
Control Sarcoidosis P-value
Sample size 101 58
Non-white 6 (5.9) 7 (12.1) 0.230
Male 32 (31.7) 32 (55.2) 0.006
Smoker 0 (0.0) 14 (24.1) <0.001
Age (yrs) 62.11 (9.07) 54.05 (9.03) <0.001
Height (cm) 166.55 (9.19) 171.89 (9.80) 0.001
Weight (kg) 77.98 (16.00) 85.65 (21.33) 0.019
BMI 28.02 (4.89) 28.84 (6.23) 0.389
Heart rate 72.10 (11.55) 74.55 (12.56) 0.225
Table 2: Clinical Characteristics
Control Sarcoidosis P-value
Sample size 101 58
% Pred Post-BD FEV1 103.31 (13.81) 85.22 (19.17) <0.001
% Pred Post-BD FVC 99.13 (12.12) 88.02 (14.60) <0.001
Table 3: Summary for 70th percentile axial slice of selected persons
Right Lung Left Lung
Healthy Sarc A Sarc B Healthy Sarc A Sarc B
D 2.33 2.21 2.15 2.36 2.25 2.18
I 0.89 0.91 0.95 0.87 0.89 0.90
C 0.09 0.07 0.04 0.10 0.08 0.05
Table 4: Summary for 40th percentile coronal slice of selected persons
Right Lung Left Lung
Healthy Sarc A Sarc B Healthy Sarc A Sarc B
D 2.35 2.22 2.16 2.33 2.25 2.14
I 0.82 0.92 0.94 0.83 0.90 0.96
C 0.13 0.07 0.04 0.13 0.07 0.03
Table 5: Summary for 80th percentile sagittal slice of selected persons
Left Lung
Healthy Sarc A Sarc B
D 2.37 2.25 2.14
I 0.81 0.86 0.96
C 0.13 0.10 0.04
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Figure 1: Slices of CT scans from subjects representative of CT abnormalities,
including healthy (column 1), diseased (column 2), and very diseased (column
3). The slices are shown for the 70th percentile axial slice (row 1), 40% coronal
slice (row 2), and 80% sagittal slice (row 3).
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Figure 2: Moran’s I (with binary eight nearest neighbors weighting) through-
out the lung. Bands represent 95% CIs. The green dashed lines indicate healthy
controls, and the purple solid lines represent subjects with sarcoidosis.
12
0.6
0.7
0.8
0.9
25 50 75
Slice % (Bottom to Top)
M
or
an
s 
I
Right Axial
0.6
0.7
0.8
0.9
25 50 75
Slice % (Bottom to Top)
M
or
an
s 
I
Left Axial
0.6
0.7
0.8
0.9
25 50 75
Slice % (Back to Front)
M
or
an
s 
I
Right Coronal
0.6
0.7
0.8
0.9
25 50 75
Slice % (Back to Front)
M
or
an
s 
I
Left Coronal
0.6
0.7
0.8
0.9
10 20 30 40 50
Slice % (Right to Left)
M
or
an
s 
I
Right Sagittal
0.6
0.7
0.8
0.9
60 70 80 90 100
Slice % (Right to Left)
M
or
an
s 
I
Left Sagittal
Figure 3: Moran’s I (8NN) throughout the lung by Scadding stage. The black
solid lines represent the mean estimate for healthy controls; Stage I (solid light
blue); Stage II (dashed blue); Stage III (dash-dotted purple); Stage IV (dotted
pink).
13
0.0
0.1
0.2
0.3
25 50 75
Slice % (Bottom to Top)
G
ea
ry
s 
C
Right Axial
0.0
0.1
0.2
0.3
25 50 75
Slice % (Bottom to Top)
G
ea
ry
s 
C
Left Axial
0.0
0.1
0.2
0.3
25 50 75
Slice % (Back to Front)
G
ea
ry
s 
C
Right Coronal
0.0
0.1
0.2
0.3
25 50 75
Slice % (Back to Front)
G
ea
ry
s 
C
Left Coronal
0.0
0.1
0.2
0.3
10 20 30 40 50
Slice % (Right to Left)
G
ea
ry
s 
C
Right Sagittal
0.0
0.1
0.2
0.3
50 60 70 80 90 100
Slice % (Right to Left)
G
ea
ry
s 
C
Left Sagittal
Figure 4: Geary’s C throughout the lung. Bands represent 95% CIs. The
green dashed lines indicate healthy controls, and the purple solid lines represent
subjects with sarcoidosis.
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Figure 5: Geary’s C throughout the lung by Scadding stage. The black solid
lines represent the mean estimate for healthy controls; Stage I (solid light blue);
Stage II (dashed blue); Stage III (dash-dotted purple); Stage IV (dotted pink).
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Figure 6: Fractal dimension throughout the lung. Bands represent 95% CIs.
The green dashed lines indicate healthy controls, and the purple solid lines
represent subjects with sarcoidosis.
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Figure 7: Fractal dimension throughout the lung by Scadding stage. The black
solid lines represent the mean estimate for healthy controls; Stage I (solid light
blue); Stage II (dashed blue); Stage III (dash-dotted purple); Stage IV (dotted
pink).
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5 Discussion
In this paper, we demonstrate the ability of spatially-varying, spatial radiomic
biomarkers to characterize pulmonary sarcoidosis. The three spatially-varying
spatial biomarkers include: Moran’s I, Geary’s C, fractal dimension, and Mate´rn
characteristic length scale & smoothness parameter. Fractal dimension, a mea-
sure of self-similarity or image roughness, shows the strongest statistical evi-
dence for differences between sarcoidosis and control images across the whole
lung, indicating sarcoidosis CT images may be best characterized by patterns
(or rather the lack thereof) of self-similarity and roughness. Interpretation of
this finding suggests that when sarcoidosis affects the lung, the inherent self-
similarity pattern in the lung is disrupted by disease, resulting in CT findings
with less self-similar and more smoothness parameters in sarcoidosis individ-
uals. By calculating the fractal dimension on slices throughout the lung, we
are able to objectively and quantitatively show that this disruption (i.e. less
self-similarity) is occurring in subjects with sarcoidosis.
While significant differences in fractal dimension between sarcoidosis sub-
jects and healthy controls are seen throughout the entire lung, disease abnor-
malities are most apparent in the top axial, middle coronal, and outer sagittal
regions, corroborating other studies that indicate CT abnormalities are predom-
inately found in the upper and central regions of the lung (Lynch 2003).
Furthermore, our results show a trend in Scadding stages, with stage III
subjects having the highest fractal dimension, in general, followed by stage I,
stage II, then stage IV. Since neither CT scan severity nor clinical symptoms
necessarily increase with increasing Scadding stages I-III, this is also consistent
with our understanding of the Scadding system. Subjects with Scadding stage
III differ from the others in that they have no bilateral hilar lymphadenopathy
or BHL. From these fractal dimension results, it appears that fractal dimension
is sensitive to the larger light areas and patterns in subjects with BHL, and
suggests that stage III subjects may visually show lung scans more similar to
healthy controls than other Scadding subjects. However, given our small sample
sizes across Scadding stages, we were not able to detect a statistical difference.
Moran’s I and Geary’s C, both measures of spatial autocorrelation, also
performed well in characterizing sarcoidosis CT findings, particularly in the
top axial and outer left/right sagittal regions. With higher Moran’s I and lower
Geary’s C, CT slices from sarcoidosis individuals showed significantly more pos-
itive spatial autocorrelation than healthy controls. These results are consistent
with our hypotheses: when disease worsens, CT nodules begin to conglomerate
into larger masses, resulting in more spatial structure. By calculating Moran’s
I and Geary’s C on slices throughout the lung, we are able to objectively and
quantitatively characterize that this conglomeration (i.e. more positive spatial
structure) is occurring in subjects with sarcoidosis.
Although similar, Geary’s C slightly outperforms Moran’s I, especially in
the axial anatomical plane. Since Geary’s C is based on weighted squared
differences, rather than the absolute value of deviations from the global mean,
it is better able to differentiate between smaller scale spatial structure, such
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as those exhibited by CT nodules. Since more CT nodules become apparent
as disease worsens across the whole lung, Geary’s C should and does perform
slightly better overall. However, when the CT nodules begin to coalesce into
larger conglomerate masses or become fibrotic, especially in the top axial region,
we should and do observe higher global spatial structure, which Moran’s I is
more suited to measure.
Our study is limited by the number of CT scans on subjects with sarcoidosis,
especially in Scadding stage I and III subjects. Since sarcoidosis is a rare disease
that has not been frequently studied, it was difficult to obtain these scans. How-
ever, we plan to perform these same analyses on the entire population from the
GRADS study in the near future. Additionally, there were some demographic
discrepancies between the healthy and diseased subjects. However, this was ac-
counted for in the analysis by adjusting for age and gender. Another limitation
in this study was the previous lack of useful ways to implement a functional
analysis, given the size of our data. We overcame this by using a novel and
unbiased binning technique.
In this study, we have successfully calculated Moran’s I, Geary’s C, and frac-
tal dimension on CT slices throughout the lung in the three anatomical planes.
Additionally, we have shown that Moran’s I, Geary’s C and fractal dimension
significantly differentiate between subjects with and without sarcoidosis in ways
that approximate what we know about the pathology of sarcoidosis. However,
we were not able to identify a statistical difference between Scadding stages
due to small group sample sizes and lack of power; yet, CT scans from pa-
tients with Scadding stages I and III appeared to trend the healthiest from our
biomarker analyses, and Scadding stage IV appeared the least healthy. Finally,
using functional regression, we were able to identify regions in the lung where
CT abnormalities tend to be prevalent.
Thus, the radiomic measures and techniques presented herein were success-
fully able to characterize computed tomography images in sarcoidosis. We are
optimistic regarding the potential application and use of our methods on other
medical imaging modalities and disease datasets in the near future.
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